Skip to main contentSkip to navigationSkip to search
ENZY  
SEK  %
Logotype
ENZY  
SEK  %
Logotype

Media

Press releases

2024

mars 27, 2024 - Regulatory press release
Notice of Annual General Meeting 2024 in Enzymatica AB (publ)
mars 14, 2024 - Regulatory press release
Enzymatica announces outcome of new rights issue
mars 11, 2024 - Non-regulatory press release
ColdZyme® certified under the new EU medical device regulation (MDR)
februari 19, 2024 - Regulatory press release
Enzymatica publishes information memorandum about rights issue of shares
februari 16, 2024 - Regulatory press release
Enzymatica’s rights issue is secured to 100 percent
februari 16, 2024 - Regulatory press release
Year-end report 2023: Scientific and regulatory progress generating international interest
februari 16, 2024 - Regulatory press release
Enzymatica’s Board of Directors decides on a new rights issue of SEK 27.4 million

2023

november 30, 2023 - Regulatory press release
Enzymatica changes Certified Adviser to Carnegie Investment Bank AB (publ)
november 7, 2023 - Regulatory press release
Interim report Q3/2023: Research results that reshape the competitive landscape
september 21, 2023 - Regulatory press release
Interim report from clinical study: ColdZyme significantly reduces rhinovirus viral load and symptoms of sore throat
augusti 22, 2023 - Regulatory press release
New study: ColdZyme breaks viral infection cycle – significantly reducing influenza viral load
juli 18, 2023 - Regulatory press release
Interim report Q2/2023: An exciting and important time ahead
maj 4, 2023 - Regulatory press release
Bulletin from Annual General Meeting of Enzymatica AB (publ)
april 27, 2023 - Regulatory press release
Interim report Q1/2023: Strong start to the year – Enzymatica’s growth journey continues according to plan
april 5, 2023 - Regulatory press release
Enzymatica publishes annual report for 2022
mars 31, 2023 - Regulatory press release
Notice of Annual General Meeting 2023 in Enzymatica AB (publ)
februari 17, 2023 - Regulatory press release
Interim report Q4/2022: A year that laid the foundation for growth

2022

november 16, 2022 - Non-regulatory press release
Enzymatica and University of Kent launch study to explore prevention of upper respiratory virus infections in elite athletes
november 2, 2022 - Regulatory press release
Interim report Q3/2022: A broader role for ColdZyme adds potential for the future
november 1, 2022 - Non-regulatory press release
New study confirms ColdZyme stops viruses causing Covid-19 from adhering to human respiratory cells
Load more